A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,000 shares of RGLS stock, worth $24,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,000
Previous 26,200 35.11%
Holding current value
$24,990
Previous $75,000 60.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.21 - $1.44 $20,262 - $24,114
16,746 Added 142.94%
28,461 $36,000
Q3 2023

Nov 14, 2023

SELL
$1.27 - $1.76 $20,434 - $28,318
-16,090 Reduced 57.87%
11,715 $16,000
Q2 2023

Aug 14, 2023

BUY
$0.87 - $1.75 $19,156 - $38,533
22,019 Added 380.56%
27,805 $40,000
Q1 2023

May 15, 2023

SELL
$0.79 - $1.61 $29,008 - $59,117
-36,719 Reduced 86.39%
5,786 $4,000
Q4 2022

Feb 14, 2023

BUY
$1.17 - $1.85 $49,730 - $78,634
42,505 New
42,505 $58,000

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $21.5M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.